Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice

[1]  Michael Wang,et al.  2021 clinical trials update: Innovations in hemophilia therapy , 2020, American journal of hematology.

[2]  D. Perry,et al.  AAV5–Factor VIII Gene Transfer in Severe Hemophilia A , 2017, The New England journal of medicine.

[3]  S. Fong,et al.  Strategy to detect pre-existing immunity to AAV gene therapy , 2017, Gene Therapy.

[4]  2017 Clinical trials update: Innovations in hemophilia therapy , 2017, American journal of hematology.

[5]  E. Seifried,et al.  Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B , 2016 .

[6]  L. Sullivan,et al.  Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression , 2016 .

[7]  V. Arruda,et al.  Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A , 2016, Journal of thrombosis and haemostasis : JTH.

[8]  D. Sabatino,et al.  Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice , 2016, Molecular therapy. Methods & clinical development.

[9]  R. Herzog,et al.  Potential for cellular stress response to hepatic factor VIII expression from AAV vector , 2016, Molecular therapy. Methods & clinical development.

[10]  R. Herzog,et al.  Clinical development of gene therapy: results and lessons from recent successes , 2016, Molecular therapy. Methods & clinical development.

[11]  X. Anguela,et al.  Adeno-associated viral vectors for the treatment of hemophilia. , 2016, Human molecular genetics.

[12]  J. Grieger,et al.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials , 2016, Molecular therapy. Methods & clinical development.

[13]  Eduard Ayuso,et al.  Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome , 2016, Molecular therapy. Methods & clinical development.

[14]  P. Ponikowski,et al.  Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure , 2015, Gene Therapy.

[15]  P. Monahan,et al.  Adeno-Associated Virus 8 (AAV8) Vector Genome Biodistribution into Body Fluids Following Single Intravenous Administration of BAX 335 Gene Therapy for Hemophilia B , 2015 .

[16]  M. Carr,et al.  Emerging and future therapies for hemophilia , 2015, Journal of blood medicine.

[17]  Xianglin Shi,et al.  Tunicamycin-induced unfolded protein response in the developing mouse brain. , 2015, Toxicology and applied pharmacology.

[18]  A. Iorio,et al.  Pharmacokinetics of plasma‐derived vs. recombinant FVIII concentrates: a comparative study , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  Michael Recht,et al.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B. , 2014, The New England journal of medicine.

[20]  Y. Wang,et al.  Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors , 2014, Gene Therapy.

[21]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[22]  P. Fagone,et al.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. , 2013, Blood.

[23]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[24]  M. Franchini,et al.  Past, present and future of hemophilia: a narrative review , 2012, Orphanet Journal of Rare Diseases.

[25]  Jeffrey S. Stonebraker,et al.  A study of variations in the reported haemophilia B prevalence around the world , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  M. Tranholm,et al.  Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[28]  Lili Wang,et al.  Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. , 2011, Molecular genetics and metabolism.

[29]  H. Morizono,et al.  Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents , 2011, Clinical and Vaccine Immunology.

[30]  R. Samulski,et al.  Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia , 2011, Gene Therapy.

[31]  A. Nienhuis,et al.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Lili Wang,et al.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. , 2011, Human gene therapy.

[33]  A. Thrasher,et al.  Codon optimization of human factor VIII cDNAs leads to high-level expression. , 2011, Blood.

[34]  John E. Murphy,et al.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. , 2010, Blood.

[35]  C. Leborgne,et al.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. , 2010, Human gene therapy.

[36]  Jeffrey S. Stonebraker,et al.  A study of variations in the reported haemophilia A prevalence around the world , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[37]  J. Prieto,et al.  Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. , 2009, Human gene therapy.

[38]  James M. Wilson,et al.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.

[39]  R. Kaufman,et al.  Antioxidants reduce endoplasmic reticulum stress and improve protein secretion , 2008, Proceedings of the National Academy of Sciences.

[40]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[41]  J. Emerson,et al.  Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. , 2006, Human gene therapy.

[42]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[43]  T. Conlon,et al.  Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  J. Gray,et al.  Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  S. Pipe,et al.  1 Bioengineering of Coagulation Factor VIII for Improved Secretion , 2004, Pediatric Research.

[46]  A. Davidoff,et al.  Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. , 2003, Blood.

[47]  K. Pasi,et al.  Haemophilias A and B , 2003, The Lancet.

[48]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[49]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[50]  R. Mitchell,et al.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Antonarakis,et al.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.

[52]  E. Tuddenham,et al.  Epidemiology of coagulation disorders. , 1992, Bailliere's clinical haematology.

[53]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[54]  P. Fogarty,et al.  Gene therapy for hemophilia: past, present and future. , 2016, Seminars in hematology.

[55]  J. Gray,et al.  transduction of murine and nonhuman primate liver efficient liver-specific human factor IX expression cassette enable highly Self-complementary adeno-associated virus vectors containing a novel , 2013 .

[56]  J. Stockman.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment , 2012 .

[57]  F. Urano,et al.  Measuring ER stress and the unfolded protein response using mammalian tissue culture system. , 2011, Methods in enzymology.

[58]  Masahito Watanabe,et al.  IN MICE , 2009 .